Product Code: RP-ID-10352478 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352478
Market Overview:
Hemophilia A Treatment Market Analysis by Patient (Pediatric, and Adult); by Treatment (Prophylaxis, and On-demand); by Therapy (Factor Replacement Therapy, and Non-Factor Replacement Therapy); by Drug Class (Vasopressin, and Coagulation Factor); and by Route of Administration (Injectable and Nasal Spray)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Global Hemophilia A Treatment Market Scope Report
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~8% |
|
Base Year Market Size (2022) |
~ USD 13 Billion |
|
Forecast Year Market Size (2033) |
~ USD 27 Billion |
Global Hemophilia A Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2033
The global hemophilia A treatment market is estimated to garner a revenue of ~ USD 27 billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 13 billion in the year 2022. The prevalence of hemophilia A is the primary factor driving the growth of the global hemophilia A treatment market. For instance, it is estimated that there are about 1 in ~5001 male births of cases of Hemophilia A in the United States (U.S.) each year.
GET A SAMPLE COPY OF THIS REPORT
Hemophilia A, also known as classic hemophilia, is caused by the deficiency of the protein factor VIII, which helps blood clot. It also leads to excessive internal and external bleeding after any damage or injury. Hemophilia is generally treated by injecting a clotting factor or plasma.
Global Hemophilia A Treatment Market: Growth Drivers and Challenges
Growth Drivers
-
Occurrence of Hemophilia A During Birth – It is estimated that only in the U. S. there are ~401 babies born with hemophilia A every year. Most people with the disease have inherited hemophilia, in which the disease is inherited from the parent to the child. Such children should suffer from a nearly absolute lack of clotting factor, making them prone to internal injuries, which leads to life-threatening damage to organs or tissues. Most babies are tested for hemophilia either through a parental genetic test before birth or a special blood test after birth.
-
Enough Access to Specialized Care for Hemophilia – It has been observed that over 69% of people with hemophilia in the U.S. have access to comprehensive and multidisciplinary care from hemophilia treatment centers (HTC)s, funded by the federal government.
-
Enough Access to Lab tests – It is believed that there is more than 24,800 business in diagnostic & medical laboratories in the U.S., as of 2022.
-
Prospective Use of Gene Therapy for Treatment – In 2022, gene therapy was observed to have brought down the annualized bleeding rates in hemophilia patients by ~91%.
Challenges
-
High Costs Involved in the Treatment
-
Limited Screening Tests for Hemophilia in Poor Economies
-
Lack of Awareness among People about Hemophilia and Its Treatments
The global hemophilia A treatment market is segmented and analyzed for demand and supply by treatment into prophylaxis and on-demand. Between these, the prophylaxis segment is anticipated to hold the largest market size by the end of 2033. The segmental growth is mostly inspired by the growing preference for the treatment method among adult patients to prevent bleeding as a result of hemophilia. Prophylaxis was observed to reduce the risk of intracranial bleeding by over 49% in patients with hemophilia.
Global Hemophilia A Treatment Market Regional Synopsis
Regionally, the global hemophilia A treatment market is studied into five major regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Amongst these markets, the market in the Asia Pacific region is projected to hold a significant share by the end of 2033. The increasing occurrence of hemophilia among the population in the region is the primary factor driving the regional market growth. For instance, in 2021, more than 1 lakh people were observed to be suffering from hemophilia.
Market Segmentation
Our in-depth analysis of the global hemophilia a treatment market includes the following segments:
|
By Patient |
|
|
By Treatment |
|
|
By Therapy |
|
|
By Drug Class |
|
|
By Route of Administration |
|
Key Companies Dominating the Global Hemophilia A Treatment Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global hemophilia A treatment market that are included in our report are Biotest AG, Pfizer Inc., CSL Behring LLC, BIOGEN INC., Kedrion S.p.A, Ferring International Center S.A., Genentech, Inc., Novo Nordisk Inc., Octapharma AG, Bayer AG, and others.
Global Hemophilia A Treatment Market: Latest Developments
-
September, 2022: Pfizer Inc. announced in collaboration with Sangamo Therapeutics, the reopening of recruitment for the phase 3 trial for the investigational gene therapy, giroctocogene fitelparvovec to treat moderately severe to severe hemophilia A.
-
March, 2019: Biotest AG announced receiving approval for the double concentrated Haemoctin(R) SDH for better treatment of hemophilia A in Europe.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Biotest AG
- Pfizer Inc.
- CSL Behring LLC
- BIOGEN INC.
- Kedrion S.p.A
- Ferring International Center S.A.
- Genentech, Inc.
- Novo Nordisk Inc.
- Octapharma AG
- Bayer AG
Related Reports
Proof of Quality & Reliability
